证券代码：688185 证券简称：康希诺 公告编号：2025-022 康希诺生物股份公司 关于参加 2025 年天津辖区上市公司投资者网上集体接待日 暨半年报业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开方式：本次活动将采用网络远程的方式举行，投资者可以登录"全景 路演"（http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路演 APP，参与本次互动交流。 一、会议类型 为进一步加强与投资者的互动交流，康希诺生物股份公司（以下简称"公司"）将 参加由天津证监局指导、天津上市公司协会及深圳市全景网络有限公司联合举办的 "2025 年天津辖区上市公司投资者网上集体接待日暨半年报业绩说明会"活动。公司将 围绕 2025 半年度业绩、公司治理、发展战略、经营状况等投资者关心的问题，通过 互动平台与投资者进行沟通交流。 二、会议召开的时间、方式 1、召开时间：2025 年 9 月 11 日（周四）15:00-17:00。 2、召开方式：本次活动将采用网络远程 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） 於 本 公 告 日 期，本 公 司 董 事 會 包 括 執 行 董 事Xuefeng YU博 士、Shou Bai CHAO博 士及王靖女士；非執行董事李志成先生；以及獨立非執行董事桂水發先生、劉建 忠先生及張耀樑先生。 证券代码：688185 证券简称：康希诺 公告编号：2025-022 （股份代號：6185） 海外監管公告 本 公 告 乃 康 希 諾 生 物 股 份 公 司（「本公司」）根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市規則第13.10B條而發表。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 發 的《康 希 諾 生 物 股 份 公 司 關 於 參 加2025 年 天 津 轄 區 上 市 公 司 投 資 者 網 上 集 體 接 待 日 暨 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康希諾生物股份公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06185 | 說明 | H 股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 132,670,900 | RMB | | 1 RMB | | 132,670,900 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 132,670,900 | RMB | | 1 RMB | | 132,670,900 | | 2. 股份分類 | 普通股 | 股份類別 | ...

Core Viewpoint - 康希诺生物股份公司 is experiencing fluctuations in stock performance, with a notable increase in stock price year-to-date, but a recent decline in the short term [1][2]. Financial Performance - As of June 30, 康希诺 reported a revenue of 3.82 billion yuan for the first half of 2025, representing a year-on-year growth of 26% [2]. - The company recorded a net profit attributable to shareholders of -1348.54 million yuan, which is an increase in loss of 94.02% compared to the previous period [2]. Stock Market Activity - On August 29, 康希诺's stock price rose by 2.04% to 82.95 yuan per share, with a trading volume of 1.05 billion yuan and a turnover rate of 1.12%, leading to a total market capitalization of 205.26 billion yuan [1]. - The stock has increased by 35.87% year-to-date, but has seen a decline of 5.25% over the last five trading days [1]. Shareholder Information - As of June 30, 康希诺 had 17,500 shareholders, a decrease of 1.92% from the previous period [2]. - The average number of circulating shares per shareholder remained at 0 shares, indicating no change [2]. Dividend Information - 康希诺 has distributed a total of 1.98 billion yuan in dividends since its A-share listing, with no dividends paid in the last three years [3].

Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, indicating significant increases and decreases in ownership percentages for various companies [1][2][3][4]. Summary by Category Increase in Holdings - The companies with the largest increases in Hong Kong Stock Connect holdings include: - Hang Seng China Enterprises (02828) with an increase of 5.48%, bringing the total holding to 6.10% - Tracker Fund of Hong Kong (02800) with an increase of 4.07%, totaling 4.76% - Anjoy Foods (02648) with an increase of 1.74%, now at 15.81% [2] - Other notable increases include: - Angelalign Technology (06699) +1.66% to 23.03% - Ganfeng Lithium (01772) +1.44% to 34.51% - East China Environmental Protection (00895) +1.44% to 43.67% [2] Decrease in Holdings - The companies with the largest decreases in Hong Kong Stock Connect holdings include: - Kinglong Motor Group (06680) with a decrease of 3.39%, now at 24.56% - Interstellar Technology (01725) with a decrease of 2.02%, totaling 10.16% - Goldwind (02208) with a decrease of 1.48%, now at 41.84% [3] - Other notable decreases include: - ZTE Corporation (00763) -1.35% to 56.09% - Longpan Technology (02465) -1.08% to 49.62% [3] Five-Day Changes - Over the last five trading days, the companies with the largest increases in holdings are: - Lens Technology (06613) +6.93% to 13.85% - ZTE Corporation (00763) +5.92% to 56.09% - Tongyu Pharmaceutical-B (02410) +5.40% to 14.72% [4] - The companies with the largest decreases in holdings over the same period include: - Hang Seng China Enterprises (02828) -14.01% to 6.10% - Tracker Fund of Hong Kong (02800) -4.36% to 4.76% [4] Twenty-Day Changes - In the last twenty days, the companies with the largest increases in holdings are: - Meizhong Jiahe (02453) +12.09% to 37.34% - Changfei Optical Fiber (06869) +10.66% to 54.73% - Tongyu Pharmaceutical-B (02410) +8.30% to 14.72% [5] - The companies with the largest decreases in holdings over the same period include: - Yisou Technology (02550) -10.13% to 47.88% - Chongqing Steel (01053) -5.27% to 31.55% [6]

Group 1 - The stock price of CanSino on August 26 was 84.82 yuan, down 3.37 yuan or 3.82% from the previous trading day [1] - The opening price was 87.70 yuan, with a high of 87.99 yuan and a low of 84.60 yuan, and the trading volume was 33,388 hands with a transaction amount of 287 million yuan [1] Group 2 - CanSino is a biopharmaceutical company focused on vaccine research, production, and commercialization, with main products including meningococcal vaccines and COVID-19 vaccines [1] - The company belongs to the bioproducts sector [1] Group 3 - According to the latest semi-annual report, CanSino achieved operating revenue of 382 million yuan in the first half of 2025, a year-on-year increase of 26% [1] - The net profit attributable to the parent company was a loss of 13.49 million yuan, significantly narrowing the loss by 94.02% compared to a loss of 225 million yuan in the same period last year [1] - During the reporting period, sales revenue from two types of combined meningococcal vaccines reached approximately 364 million yuan, a year-on-year increase of 38.43% [1] Group 4 - On August 26, the net outflow of main funds for CanSino was 71.34 million yuan, accounting for 0.73% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow was 67.14 million yuan, representing 0.69% of the circulating market value [1]

Core Viewpoint - The Vice President of the company, Wang Jing, has reduced his holdings in CanSino Biologics (06185) by selling 4,600 shares at a price of HKD 51.5 per share, totaling HKD 236,900 [1] Summary by Relevant Sections - **Shareholding Reduction** - Wang Jing sold 4,600 shares of CanSino Biologics at a price of HKD 51.5 per share, amounting to a total of HKD 236,900 [1] - **Post-Transaction Holdings** - After the sale, Wang Jing's remaining shareholding is 14,200 shares, representing a holding percentage of 0.01% [1]

Summary of Key Points - On August 22, the Deputy General Manager Wang Jing reduced his holdings in CanSino Biologics (06185) by selling 4,600 shares at a price of HKD 51.5 per share, totaling HKD 236,900 [1] - After the sale, Wang Jing's remaining shareholding is 14,200 shares, which represents a holding percentage of 0.01% [1]

Core Viewpoint - UBS has raised the target price for CanSino Biologics (06185) to HKD 66.6 and reiterated a "Buy" rating, citing better-than-expected second-quarter performance and significant potential in early pipeline products and licensing opportunities [1] Financial Performance - CanSino's revenue growth accelerated to 38% in Q2, compared to 20% in Q1 [1] - The net loss narrowed to RMB 2 million, with a total net loss of RMB 13 million for the first half, a 94% reduction year-on-year, which was better than UBS's forecast of RMB 31 million loss [1] Earnings Forecast - UBS has adjusted its earnings per share forecasts for 2025 to 2027 from RMB 0.01, 1.16, and 2.39 to RMB 0.24, 1.16, and 2.55 respectively [1] Market Position and Guidance - UBS reaffirms CanSino as a preferred stock in the vaccine sector, anticipating accelerated profit growth [1] - The management has reiterated a full-year revenue guidance of RMB 1 billion [1] Sales Projections - UBS has increased the peak sales forecast for MCV4 from RMB 1.1 billion to RMB 1.3 billion, expecting approval for expanded indications and improved penetration rates [1]

Core Viewpoint - UBS reports that CanSino Biologics (06185) performed slightly better than expected in Q2, with revenue growth accelerating to 38% compared to 20% in Q1, and net loss narrowing to 2 million RMB, with a total net loss of 13 million RMB in the first half, a 94% reduction year-on-year, which is less than the bank's forecast of a 31 million RMB loss [1] Financial Performance - Revenue growth in Q2 reached 38%, an increase from 20% in Q1 [1] - Net loss for Q2 was 2 million RMB, while the total net loss for the first half was 13 million RMB, a significant reduction of 94% compared to the same period last year [1] - The actual loss was lower than UBS's forecast of 31 million RMB for the first half [1] Price Target and Earnings Forecast - UBS raised the target price for CanSino from 47 HKD to 66.6 HKD and reiterated a "Buy" rating [1] - Earnings per share forecasts for 2025 to 2027 were adjusted from 0.01, 1.16, and 2.39 RMB to 0.24, 1.16, and 2.55 RMB respectively [1] Market Position and Growth Potential - UBS maintains that CanSino is a preferred stock in the vaccine sector, anticipating accelerated profit growth [1] - The management reaffirmed the annual revenue guidance of 1 billion RMB [1] - Sales forecast for MCV4 was increased from 1.1 billion RMB to 1.3 billion RMB, with expectations for approval of expanded indications and increased penetration rates [1]